SUBSCRIBE
SUBSCRIBE

Alnylam Pharmaceuticals

NEWS
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Deals
Why Amgen Should Turn Its Attention to Alnylam
November 13, 2015
 · 
3 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Policy
Alnylam Slaps Dicerna With Trade Secret Lawsuit
June 11, 2015
 · 
4 min read
Biowarfare Company Emergent's Cancer Spinoff Aptevo Therapeutics to Employ 70 - 90 in Seattle
Business
Former Sanofi Exec and Viehbacher Protoge to Join Alnylam as Senior VP
June 8, 2015
 · 
3 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Business
Booming Alnylam to Take Over Vertex’s Large Space in Cambridge
April 6, 2015
 · 
2 min read
Job Trends
1,075 New Jobs to be Added by 11 Life Science Firms in Massachusetts: Amgen, Alnylam, Biogen Idec, Inc. (North Carolina), GE Healthcare Bio-Sciences, Quest Diagnostics, Alkermes, Baxter Healthcare, Merrimack, Synageva BioPharma, Philips Electronics, SMC
March 19, 2015
 · 
2 min read
Analysts Not Sold On Medivation’s Xtandi as Breast Cancer Drug
BioCapital
Alnylam’s “Incredibly Deep” Pipeline Continues to Impress As Commercial Stage Looms, Says Analyst
February 27, 2015
 · 
2 min read
BIOCEO15 Gilead COO Says 6-Week Timeline for Hep C Course Unrealistic, Outlines NASH, Cancer Strategies
Job Trends
BIOCEO15: Alnylam CEO Says Cash-Flush Company Will Hire 100 in 2015
February 10, 2015
 · 
3 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Deals
Sanofi’s Increased Stake in Alnylam Pharmaceuticals Points Toward a Possible Acquisition
January 30, 2015
 · 
2 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Genetown
Alnylam Banks $450 Million to Fund Ambitious Pipeline Goals
January 20, 2015
 · 
2 min read
Load More
AWARDS
  • 2022 Best Places to Work
  • 2023 Best Places to Work
  • 2024 Best Places to Work
JOBS
IN THE PRESS
Genetown
Alnylam Announces that the United Kingdom’s MHRA Grants Early Access to Lumasiran
July 13, 2020
 · 
11 min read
Deals
Blackstone Announces $4.6 Billion Final Close of Life Sciences Fund
July 9, 2020
 · 
2 min read
Drug Development
Alnylam Reports New 12-Month Interim Data From the ENVISION Phase 3 Study of Givosiran in Acute Hepatic Porphyria
June 30, 2020
 · 
17 min read
Genetown
Alnylam to Host Seventh Annual “RNAi Roundtable” Webcast Series
June 18, 2020
 · 
3 min read
Genetown
Alnylam to Webcast Presentation at Bank of America Securities 2020 Napa Biopharma Conference
June 17, 2020
 · 
1 min read
Drug Development
Alnylam Announces Publication of ENVISION Phase 3 Study Results for Givosiran in the New England Journal of Medicine
June 10, 2020
 · 
16 min read
Drug Development
Alnylam Presents Positive Phase 3 Results from ILLUMINATE-A Study of Lumasiran, an Investigational RNAi Therapeutic for Treatment of Primary Hyperoxaluria Type 1
June 7, 2020
 · 
17 min read
Genetown
Alnylam Announces Recipients of Second Annual Advocacy for Impact Grants Program
June 2, 2020
 · 
5 min read
Drug Development
Alnylam to Webcast Conference Call Discussing Full Results from ILLUMINATE-A Phase 3 Study of Lumasiran at ERA-EDTA International Congress
June 1, 2020
 · 
2 min read
Genetown
Alnylam to Webcast Presentations at Upcoming June 2020 Investor Conferences
May 26, 2020
 · 
2 min read
Load More